ClinicalTrials.gg
Not yet recruitingNCT06777342Updated Jan 15, 2025

Effect of Preoperative Sleep Intervention on Postoperative Delirium in Adult Patients Undergoing Cardiac Surgery

An interventional study of Cognitive behavioral therapy intervention and Melatonin intervention in Delirium - Postoperative, Sleep Problems and CABG, sponsored by Yan Fuxia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Yan Fuxia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,281
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, controlled clinical trial aimed to determine whether preoperative sleep interventions could reduce the incidence of adverse outcomes, such as postoperative delirium, in adult patients undergoing cardiac surgery. The study will include adult patients undergoing coronary artery bypass grafting and/or valve surgery with concomitant sleep disorders, as assessed by the Pittsburgh Sleep Quality Index. All participants will be randomly assigned to placebo, placebo + cognitive behavioral therapy, and melatonin + cognitive behavioral therapy in a 1:1:1 ratio. The primary outcome is the incidence of postoperative delirium within 7 days after surgery or before discharge, and secondary outcomes include postoperative cognitive function, sleep quality, and severity and duration of delirium. The results of this study will provide suggestions for the prevention of delirium after cardiac surgery.

02

Conditions studied

  • Delirium - Postoperative
  • Sleep Problems
  • CABG
  • Valve Surgery

Browse trials for

03

In context

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

This study's planned enrollment of 1,281 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.

Browse Emergence Delirium studies →

Lead sponsor

Yan Fuxia is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Scheduled for elective coronary artery bypass grafting and/or valve surgery.
  3. Preoperative Pittsburgh Sleep Quality Index (PSQI) score ≥ 5.

Exclusion criteria

Exclusion Criteria:

  1. History of neurosurgery, cerebral hemorrhage, cerebral infarction, delirium, dementia, or other neurological diseases.
  2. History of mental illness.
  3. Habitual heavy drinking.
  4. (ASA) grade IV or above.
  5. Severe hepatic dysfunction ( Grade C) or renal dysfunction (chronic kidney disease stages 3-4).
  6. to melatonin use, such as allergies to melatonin-related ingredients.
  7. Currently taking melatonin, melatonin receptor agonists, sleep-related medications, sedatives, antipsychotic medications, or opioids.
  8. Inability to communicate due to hearing or speech impairment, or refusal to provide .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,281 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Other: Placebo intervention

  • Experimental
    Placebo and cognitive behavioral therapy intervention group

    Behavioral: Cognitive behavioral therapy intervention · Other: Placebo intervention

  • Experimental
    Melatonin and cognitive behavioral therapy intervention group

    Behavioral: Cognitive behavioral therapy intervention · Dietary Supplement: Melatonin intervention

Interventions

  • BehavioralCognitive behavioral therapy intervention

    The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.

  • Dietary supplementMelatonin intervention

    Patients in the melatonin intervention group are required to take an oral melatonin of 5 mg at 30-60 minutes before sleep (administered at 21:00) nightly for 7 to 14 days before surgery. The melatonin was provided by Kangenbei Pharmaceutical Co., LTD. (Hangzhou, Zhejiang, China).

  • OtherPlacebo intervention

    Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).

06

What researchers measure

Primary outcomes

  1. The incidence of postoperative delirium

    Time frame: Postoperative 7 days or before discharge

Secondary outcomes

  1. Postoperative sleep quality

    The sleep quality was evaluated using the Actigraph model wGT3X-BT and the Sleep Quality and Nighttime Restlessness Scale (SQNRS) score. Subjects wore the Actigraph wGT3X-BT activity monitor from the beginning of their hospital admission until 7 days after surgery or before discharge. The device will record parameters such as total sleep time, wake time after falling asleep, number of awakenings, average wake time, and sleep efficiency during the first 7 days after surgery or before discharge to assess the subjects' sleep quality. Additionally, the SQNRS score was used to evaluate patients' subjective sleep quality during the same period. The SQNRS score ranges from 0 to 10, with higher scores indicating better sleep quality.

    Time frame: Postoperative 7 days or before discharge

  2. Postoperative cognitive function

    The Montreal Cognitive Assessment (MoCA) will be administered to evaluate the cognitive function of the patients 7 days after surgery or before discharge. The MoCA has a total score of 30 points, with a score above 26 indicating normal cognitive function.

    Time frame: The 7th day after surgery or before discharge

  3. Duration and severity of delirium

    Time frame: Postoperative 7 days or before discharge

  4. Postoperative mood and anxiety

    The Hospital Anxiety and Depression Scale (HADS) will be utilized to evaluate the mood and anxiety levels of the patients during the first 7 days after surgery or before discharge. The HADS scale comprises two subscales, totalling 14 items: 7 items assess anxiety, and the other 7 assess depression. Each item is scored on a scale of 0 to 3, with each subscale totalling up to 21 points. Interpretation of the scores is as follows: 0-7 indicates a normal state, 8-10 suggests mild anxiety/depression, 11-14 indicates moderate anxiety/depression, and 15-21 suggests severe anxiety/depression.

    Time frame: The 7th day after surgery or before discharge

Other outcomes

  1. Postoperative pain score

    The Visual Analogue Scale (VAS) will be employed to assess the pain levels of patients during the first 7 days after surgery or before discharge. A VAS score ranges from 0 to 10, with 1-3 indicating mild pain, 4-6 indicating moderate pain, and 7-10 indicating severe pain.

    Time frame: Postoperative 7 days or before discharge

  2. Types and doses of postoperative sedative and analgesic drugs

    Time frame: Postoperative 7 days or before discharge

  3. Postoperative nausea and vomiting

    The frequency of nausea and vomiting will be recorded daily for 7 days following surgery or before discharge, as documented during bedside consultations.

    Time frame: Postoperative 7 days or before discharge

  4. Postoperative markers of oxidative stress and inflammation

    Within 24 hours after surgery, levels of malondialdehyde (MDA), ascorbic acid (AA), dehydroascorbic acid (DHA), and C-reactive protein (CRP) will be determined from 5 mL of venous blood drawn from the patients.

    Time frame: 24 hours after surgery

  5. Postoperative mechanical ventilation time and Intensive Care Unit stay time

    Time frame: Postoperative 7 days or before discharge

  6. Length of hospital stay

    Time frame: 30 days after surgery

  7. In-hospital mortality

    Time frame: Postoperative 7 days or before discharge

  8. Serious adverse cardiovascular events

    Time frame: Postoperative 7 days or before discharge

  9. Long-term survival

    Survival information will be obtained through telephone follow-up.

    Time frame: 30 days after surgery

  10. Long-term survival

    Survival information will be obtained through telephone follow-up.

    Time frame: 12 months after surgery

  11. Long-term sleep quality

    The patients' sleep quality will be assessed through telephone follow-up using the Sleep Quality and Nighttime Restlessness Scale (SQNRS). The SQNRS score ranges from 0 to 10, with higher scores indicating better sleep quality.

    Time frame: 30 days after surgery

  12. Long-term sleep quality

    The patients' sleep quality will be assessed through telephone follow-up using the Sleep Quality and Nighttime Restlessness Scale (SQNRS). The SQNRS score ranges from 0 to 10, with higher scores indicating better sleep quality.

    Time frame: 12 months after surgery

  13. Long-term pain

    The patients' long-term pain will be assessed through telephone follow-up using the Visual Analogue Scale (VAS). A VAS score ranges from 0 to 10, with 1-3 indicating mild pain, 4-6 indicating moderate pain, and 7-10 indicating severe pain.

    Time frame: 30 days after surgery

  14. Long-term pain

    The patients' long-term pain will be assessed through telephone follow-up using the Visual Analogue Scale (VAS). A VAS score ranges from 0 to 10, with 1-3 indicating mild pain, 4-6 indicating moderate pain, and 7-10 indicating severe pain.

    Time frame: 12 months after surgery

  15. Total hospitalization costs

    Time frame: 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2025, 10 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 10 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 15, 2025
StartEst.
Feb 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06777342
Lead sponsor
Yan Fuxia
Responsible party
Yan Fuxia (principal investigator, Chinese Academy of Medical Sciences, Fuwai Hospital) — Sponsor-investigator
First posted
Jan 15, 2025
Start date
Feb 1, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 15, 2025

Study contacts

Fuxia Yan
Contact
yanfuxia@sina.com
010 88396628

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion